Article

Molnupiravir, an Oral Antiviral Treatment for COVID-19

2021-06-17

Abstract excerpt

<h4>Background</h4> Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19 ( ClinicalTrials.gov N...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f2ca05bd-d993-53fa-8219-fab6cbcc8e47
DOI: 10.1101/2021.06.17.21258639

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molnupiravir, an Oral Antiviral Treatment for COVID-19DOI 10.1101/2021.06.17.21258639Read

Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity Read

Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity Read

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2Semantic proximity Read

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Semantic proximity Read

The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19Semantic proximity Read

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical TrialSemantic proximity Read

Effectiveness of Community-Based Oral Antiviral Treatments Against Severe COVID-19 Outcomes in Victoria, Australia, 2022: An Observational StudySemantic proximity Read

Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studySemantic proximity Read

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19Semantic proximity Read

Molnupiravir Use and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity Read

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivitySemantic proximity Read